Jump to ContentJump to Main Navigation
Human Genome Epidemiology, 2nd EditionBuilding the evidence for using genetic information to improve health and prevent disease$
Users without a subscription are not able to see the full content.

Muin Khoury, Sara Bedrosian, Marta Gwinn, Julian Higgins, John Ioannidis, and Julian Little

Print publication date: 2009

Print ISBN-13: 9780195398441

Published to Oxford Scholarship Online: May 2010

DOI: 10.1093/acprof:oso/9780195398441.001.0001

Show Summary Details
Page of

PRINTED FROM OXFORD SCHOLARSHIP ONLINE (www.oxfordscholarship.com). (c) Copyright Oxford University Press, 2019. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a monograph in OSO for personal use (for details see www.oxfordscholarship.com/page/privacy-policy).date: 16 July 2019

A Rapid-ACCE review of CYP2C9 and VKORC1 allele testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding

A Rapid-ACCE review of CYP2C9 and VKORC1 allele testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding

Chapter:
(p.620) 31 A Rapid-ACCE review of CYP2C9 and VKORC1 allele testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding
Source:
Human Genome Epidemiology, 2nd Edition
Author(s):

Monica R. McClain

Glenn E. Palomaki

Margaret Piper

James E. Haddow

Publisher:
Oxford University Press
DOI:10.1093/acprof:oso/9780195398441.003.0031

This chapter describes the results from a Rapid-ACCE review (Analytic validity, Clinical validity, Clinical utility, and Ethical, legal, and social implications), designed to facilitate the transition of genetic tests from investigational settings to clinical and public health practice. The ACCE model is composed of a standard set of 44 questions, and builds on the methodologies and terminology introduced by the Secretary's Advisory Committee on Genetic Testing. In this review, the genetic test is CYP2C9 and VKORC1 genotyping, the disorder is serious bleeding, and the clinical scenario is adults at elevated risk for thrombotic events who are candidates for warfarin. These two genes are responsible for much of the observed differences in drug metabolism between individuals.

Keywords:   Rapid-ACCE review, genetic tests, public health practice, CYP2C9, VKORC1, warfarin, serious bleeding, thrombotic events

Oxford Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.

Please, subscribe or login to access full text content.

If you think you should have access to this title, please contact your librarian.

To troubleshoot, please check our FAQs , and if you can't find the answer there, please contact us .